Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Payables (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Payables for 8 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 41.09% year-over-year to $5.1 million, compared with a TTM value of $5.1 million through Sep 2025, down 41.09%, and an annual FY2024 reading of $8.6 million, down 3.64% over the prior year.
  • Payables was $5.1 million for Q3 2025 at X4 Pharmaceuticals, down from $7.7 million in the prior quarter.
  • Across five years, Payables topped out at $11.1 million in Q1 2025 and bottomed at $2.4 million in Q3 2021.
  • Average Payables over 5 years is $6.2 million, with a median of $6.0 million recorded in 2023.
  • The sharpest move saw Payables surged 147.68% in 2021, then tumbled 41.09% in 2025.
  • Year by year, Payables stood at $4.3 million in 2021, then surged by 81.58% to $7.8 million in 2022, then grew by 15.04% to $8.9 million in 2023, then dropped by 3.64% to $8.6 million in 2024, then tumbled by 41.39% to $5.1 million in 2025.
  • Business Quant data shows Payables for XFOR at $5.1 million in Q3 2025, $7.7 million in Q2 2025, and $11.1 million in Q1 2025.